Cough News and Research

RSS
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

Amgen announces availability of Kyprolis (carfilzomib) in the UK for treatment of relapsed multiple myeloma

New evidence highlights benefits and harms of using artificial mesh for surgical repair of vaginal prolapse

New evidence highlights benefits and harms of using artificial mesh for surgical repair of vaginal prolapse

Cherry-flavoured e-cigarette users may be exposed to potentially harmful chemical

Cherry-flavoured e-cigarette users may be exposed to potentially harmful chemical

New case of MERS CoV confirmed in Thailand, other states in WHO South-East Asia Region cautioned to remain vigilant

New case of MERS CoV confirmed in Thailand, other states in WHO South-East Asia Region cautioned to remain vigilant

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

Oral drug ivacaftor appears to be safe, beneficial to pre-school children with specific type of cystic fibrosis

American College of Cardiology to honor LA BioMed researcher with Distinguished Teacher Award

American College of Cardiology to honor LA BioMed researcher with Distinguished Teacher Award

Music therapy in conjunction with standard rehabilitation benefits COPD patients

Music therapy in conjunction with standard rehabilitation benefits COPD patients

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Kanuma approved as first treatment for patients with LAL deficiency

Kanuma approved as first treatment for patients with LAL deficiency

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

XARELTO reduces rates of major bleeding, recurrent blood clots in people with deep vein thrombosis

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

People who experience persistent heartburn despite over-the-counter treatments need to check with their doctors

People who experience persistent heartburn despite over-the-counter treatments need to check with their doctors

SLU infectious diseases experts answer flu season questions

SLU infectious diseases experts answer flu season questions

New data shows ALS-008176 drug safe and effective against RSV infection

New data shows ALS-008176 drug safe and effective against RSV infection

Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.